Cryolife Inc (NYSE:CRY) Receives $33.67 Consensus Target Price from Analysts

Shares of Cryolife Inc (NYSE:CRY) have earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $33.67.

Several brokerages recently issued reports on CRY. ValuEngine upgraded Cryolife from a “hold” rating to a “buy” rating in a report on Friday, March 20th. First Analysis lowered Cryolife from a “strong-buy” rating to an “outperform” rating in a report on Friday, February 14th. Canaccord Genuity lowered Cryolife from a “buy” rating to a “hold” rating and cut their price objective for the stock from $32.00 to $29.00 in a report on Friday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Cryolife in a research report on Friday, February 14th.

Shares of NYSE:CRY traded up $1.30 during midday trading on Monday, hitting $16.26. 698,100 shares of the stock were exchanged, compared to its average volume of 284,658. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.97 and a current ratio of 4.15. Cryolife has a 52-week low of $12.63 and a 52-week high of $33.00. The business’s fifty day simple moving average is $24.46 and its two-hundred day simple moving average is $25.81. The company has a market capitalization of $584.64 million, a PE ratio of 406.60, a P/E/G ratio of 54.18 and a beta of 0.86.

Cryolife (NYSE:CRY) last announced its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. Cryolife had a return on equity of 4.16% and a net margin of 0.62%. The business had revenue of $69.70 million during the quarter, compared to analyst estimates of $72.95 million. As a group, equities analysts anticipate that Cryolife will post 0.14 EPS for the current year.

In other Cryolife news, VP Jean F. Holloway sold 8,458 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $30.00, for a total transaction of $253,740.00. Following the transaction, the vice president now directly owns 67,322 shares of the company’s stock, valued at $2,019,660. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.40% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in shares of Cryolife by 44.9% in the third quarter. Russell Investments Group Ltd. now owns 17,309 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 5,367 shares during the last quarter. Metropolitan Life Insurance Co NY grew its position in shares of Cryolife by 10.0% in the third quarter. Metropolitan Life Insurance Co NY now owns 12,156 shares of the medical equipment provider’s stock valued at $330,000 after purchasing an additional 1,107 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Cryolife in the fourth quarter valued at about $87,000. First Trust Advisors LP grew its position in shares of Cryolife by 9.7% in the third quarter. First Trust Advisors LP now owns 74,361 shares of the medical equipment provider’s stock valued at $2,019,000 after purchasing an additional 6,559 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Cryolife in the fourth quarter valued at about $109,000. 75.04% of the stock is currently owned by hedge funds and other institutional investors.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Hang Seng Index (HSI)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.